Unlock instant, AI-driven research and patent intelligence for your innovation.

Biomarkers for subtypes of cervical cancer

Inactive Publication Date: 2011-09-15
UNIV OSLO HF
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011]Thus, in some embodiments, the present invention provides improved biomarkers and methods for predicting a predisposition, diagnosing, predicting the likelihood of recurrence, predicting the prognosis for patient with a subtype of cervical cancer.

Problems solved by technology

Cervical cancer is one of the most common malignancies affecting women worldwide and a major cause of cancer death for women globally.
Tumor stage, size, and lymph node involvement are the most powerful markers of aggressive disease, but do not fully account for the observed variability in outcome and are not biologically founded.
Moreover, pronounced intratumor heterogeneity in the gains and losses exists within the tumors, reflecting a high genetic instability.
The consequences of these alterations for the tumor phenotype are difficult to predict, since large chromosomal regions involving multiple genes are generally affected and some aberrations may be random events without biological significance.
Genetic events promoting tumor evolution and treatment resistance have, however, not been explored on a genome wide scale, and their biological meaning has not been addressed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers for subtypes of cervical cancer
  • Biomarkers for subtypes of cervical cancer
  • Biomarkers for subtypes of cervical cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

Gene Dosage, Expression, and Ontology Analysis Identifies Driver Genes in the Carcinogenesis and Chemoradioresistance of Cervical Cancer

[0151]Integrative analysis of gene dosage, expression, and ontology (GO) data was performed to discover driver genes in the carcinogenesis and chemoradioresistance of cervical cancers. Gene dosage and expression profiles of 102 locally advanced cervical cancers were generated by microarray techniques. Fifty-two of these patients were also analyzed with the Illumina expression method to confirm the gene expression results. An independent cohort of 41 patients was used for validation of gene expressions associated with clinical outcome. Statistical analysis identified 29 recurrent gains and losses and 3 losses (on 3p, 13q, 21q) associated with poor outcome after chemoradiotherapy. The intratumor heterogeneity, assessed from the gene dosage profiles, was low for these alterations, showing that they had emerged prior to many other alterations and probab...

example 2

Integrated Genomic and Transcriptional Profiling of Cervical Cancers Reveals Candidate Biomarkers of Chemoradioresistant Disease

[0188]Purpose. Gene dosage alterations like gains and losses influence gene expressions and are motive forces for tumor development and progression. The purpose of this work was to identify gene dosage alterations and the affected transcripts in locally advanced cervical cancers, and explore their role in development of chemoradioresistant disease.

[0189]Materials and Methods. A total of 102 patients with locally advanced squamous cell carcinoma of the uterine cervix were included. All patients received radiotherapy with or without cisplatin. Tumor biopsies were taken before the start of treatment and used for the molecular profiling. Gene dosage and expression profiling was performed by array comparative genomic hybridization (aCGH) and cDNA microarray analysis, respectively. Pairwise data were available for 95 patients. The GISTIC and LASSO methods, suitab...

example 3

RYBP Protein Expression and Cellular Localization

Materials and Methods

[0192]Immunohistochemistry. Pre-treatment tumor specimens were available in sufficient amounts for immunohistochemical study in 150 patients. Formalin-fixed, paraffin-embedded tissue sections from the patients and three cell lines (HeLa, SiHa, CaSki) were immunostained with RYBP (LifeSpan BioSciences, Seattle, Wash.) using the Dako EnVision™ FLEX+ detection system (Dako Corp., Denmark) manually. Heat induced epitope retrieval was performed with a PT Link using Envsion™ FLEX Target Retrieval Solution at high pH (Tris / EDTA buffer pH 9). Incubation time for the primary antibody was 45 minutes at room temperature. EnVision™ FLEX+ Rabbit LINKER was used for signal amplification of primary antibody and the reaction was visualized by EnVision™ FLEX DAB+ Chromogen. Placenta was used as positive control. As negative control, the primary antibody was substituted with normal rabbit IgG of the same concentration as the primar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present invention relates to biomarkers for chemoradioresistant subtypes of cervical cancer. In particular the present invention relates to a method for predicting a predisposition to a chemoradioresistant cervical cancer in a subject, a method for diagnosing a chemoradioresistant cervical cancer in a subject, a method for predicting the likelihood of recurrence of cervical cancer in a cervical cancer patient under treatment, and a method for predicting the prognosis for a patient with a chemoradioresistant cervical cancer.

Description

[0001]This application claims the benefit of U.S. Provisional Appl. 61 / 312,875, filed Mar. 11, 2010, the entire contents of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to biomarkers for subtypes of cervical cancer. In particular the present invention relates to a method for predicting a predisposition to a chemoradioresistant cervical cancer in a subject, a method for diagnosing a chemoradioresistant cervical cancer in a subject, a method for predicting the likelihood of recurrence of cervical cancer in a cervical cancer patient under treatment, and a method for predicting the prognosis for a patient with a chemoradioresistant cervical cancer.BACKGROUND OF THE INVENTION[0003]Cervical cancer is one of the most common malignancies affecting women worldwide and a major cause of cancer death for women globally. Radiotherapy combined with cisplatin is the treatment of choice at the locally advanced stages. Improved therapy is neede...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C40B30/00C12Q1/68G01N33/574C40B30/04
CPCC12Q1/6886C12Q2600/106C12Q2600/118C12Q2600/136C12Q2600/158C12Q2600/16G01N33/57411G01N2333/4703G01N2333/4704G01N2333/4706G01N2333/91131
Inventor LYNG, HEIDILANDO, MALIN
Owner UNIV OSLO HF